171730P.pdf   09/10/2018  Jan Vallejo  v.  Amgen, Inc.
   U.S. Court of Appeals Case No:  17-1730
                          and No:  17-2593
   U.S. District Court for the District of Nebraska - Omaha   
   [PUBLISHED] [Smith, Author, with Beam and Colloton, Circuit Judges] 
   Civil case - Civil procedure. In this action alleging plaintiff's 
   deceased's use of the biologic Enbrel causes him to develop 
   myelodysplastic syndrome, the district court did not abuse its discretion 
   in limiting the scope of plaintiff's general causation discovery; the 
   district court did not rely on misrepresented facts by defendant in 
   issuing its discovery orders; any error in limiting plaintiff's ability to 
   cross-examine defendant's discovery expert was harmless as the court did 
   not rely on his opinion in reaching its decision that the scope of 
   plaintiff's discovery demand was unreasonable; the district court was 
   under no obligation to order defendant to provide plaintiff the materials 
   the FDA requests - but does not require - from pharmaceutical companies 
   when it evaluates safety risks; the district court did not abuse its 
   discretion in imposing Rule 11 sanctions against plaintiff for abusing the 
   discovery process, disregarding the court's directives and repeatedly 
   relitigating issues decided by the court; the imposition of sanctions was 
   also permitted under 28 U.S.C. Sec. 1927 and the court's inherent power.